Zenith Capital Corp. (ZHCLF)
Zenith Capital Corp. operates in the Biotechnology industry of the Healthcare sector, headquartered in Calgary, AB, CA. The stock last traded at $0.05, up 0.00% on the session, giving a market capitalisation of $8.0M. On trailing twelve-month figures it carries a trailing P/E of -1.03, a net margin of -1531.2%. Its beta of 687.84 implies it has historically moved more than the broad market.
Zenith Capital Corp., a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. The company's lead compound ZEN-3694, which is in Phase 2 clinical trial for the treatment of metastatic castration resistant prostate cancer in collaboration with Astellas and Newsoara, as well as advanced or metastatic triple-negative breast cancer in collaboration with Pfizer. It has a research and development collaboration agreement with the National Cancer Institute. The company was formerly known as Zenith Epigenetics Corp. and changed its name to Zenith Capital Corp. in August 2016. Zenith Capital Corp. was incorporated in 2013 and is headquartered in Calgary, Canada.
Zenith Capital Corp. is most often compared with the following Healthcare names: